Treating Patients with SCLC with Driver Mutations

Opinion
Video

The Oncology Brothers and Eric Singhi, MD, provide clinical insights on the treatment of patients with small cell lung cancer with driver mutations.

Recent Videos
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Biomarker research is needed to better ascertain patient benefit with tarlatamab among those with relapsed extensive-stage small cell lung cancer.
Less lymphocyte depletion with twice-daily radiotherapy warrants further assessment to optimize the synergistic effect of radiotherapy and immunotherapy.
The recent accelerated approval of tarlatamab marks a significant milestone in treating relapsed extensive-stage small cell lung cancer (ES-SCLC).
Twice-daily thoracic radiotherapy appeared to confer less leukocyte and lymphocyte depletion compared with once-daily radiation in LS-SCLC.
Tarlatamab has demonstrated superiority to lurbinectedin as a treatment for patients with ES-SCLC who have progressed after frontline chemoimmunotherapy.
The clinical adoption of twice-daily accelerated radiotherapy has been limited in North America despite improved outcomes, according to Bin Gui, MD.
Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.
CAR T-cell therapies or other agents that impact the immune system in the long term may be important to keep in mind for the management of SCLC.
Employing patient-reported outcomes may help include those with small cell lung cancer in the shared decision-making process.
Related Content
Data from the DeLLphi-304 trial support the full approval of tarlatamab in this extensive-stage small cell lung cancer population.

Tarlatamab Earns Traditional FDA Approval in ES-SCLC

Russ Conroy
November 19th 2025
Article

Data from the DeLLphi-304 trial support the full approval of tarlatamab in this extensive-stage small cell lung cancer population.

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Data show that XCR1-positive conventional type 1 dendritic cells may play a role as mediators of response to atezolizumab in extensive-stage SCLC.

Atezolizumab/Vaccine Combo May Show Long-Term Survival in ES-SCLC

Russ Conroy
November 15th 2025
Article

Data show that XCR1-positive conventional type 1 dendritic cells may play a role as mediators of response to atezolizumab in extensive-stage SCLC.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Findings from the RATIONALE-312 trial support tislelizumab plus chemotherapy as a frontline treatment option in extensive-stage small cell lung cancer.

Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC

Russ Conroy
October 25th 2025
Article

Findings from the RATIONALE-312 trial support tislelizumab plus chemotherapy as a frontline treatment option in extensive-stage small cell lung cancer.

Data from IDeate-Lung01 reveal a disease control rate exceeding 90% with infinatamab deruxtecan.

I-DXd Yields Promising Intracranial Efficacy in ES-SCLC Population

Kristi Rosa
October 19th 2025
Article

Data from IDeate-Lung01 reveal a disease control rate exceeding 90% with infinatamab deruxtecan.